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Emerging evidence indicates that the causative agent of tuberculosis ismore genetically and
functionally diverse than appreciated previously. The impact of this variation on the clinical
manifestation of the disease remains largely unknown. In addition, there exists significant
variability in the immune status of the host governing susceptibility to tuberculosis. The
effect of these variations on the host pathogen interaction was investigated by taking vary-
ing pathogen phenotypes (virulent H37Rv, a-virulent H37Ra and amultidrug resistant strain
#591) and varying host (18 MDR-TB and 16 fresh TB patients and 10 healthy, BCG-vaccinated
individuals). The key question waswhether the intracellular survival ofMycobacterium tuber-
culosis (MTB) in human monocyte-derived macrophages (MDM), an attribute of pathogenic
potential, can be modulated by the immune status of the hosts or phenotype of MTB.
The findings of this study indicate that induction of TNF-amay not be a global indicator of
virulence of a strain. TNF-a release may be differentially regulated in response to the same
strain depending upon the immune status of the host. Moreover, the phenotype of the
infecting MTB and the host’s immune status played a comparable role in the intracellular
survival of MTB. This picture supports the hypothesis that in addition to the phenotype var-
iation of the mycobacteria, the immune status of an individual will greatly influence the
outcome of the host–pathogen interaction. These results may have a bearing on the future
endeavors in vaccine development and TB control strategy.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.-African Society for Mycobacteriology. All rights reserved.
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The rational design of amore effective vaccine and better ther-
apeutic agents against tuberculosis requires an understanding
of the pathogenesis and immune response [1]. The relative
inefficiency of BCG vaccine and the recent spread of
multidrug-resistant (MDR) and extensively drug-resistant
(XDR) tuberculosis (TB) necessitates an in-depth analysis of
the host and the pathogen factors that would finally be rele-
vant as considered parameters towards the ultimate goal of
TB control.
Central to understanding the pathogenesis of TB is the
dynamics of the interaction between Mycobacterium tuberculo-
sis (MTB) and macrophages where both the pathogen and the
host factors contribute to the final outcome.
Strain variation of MTB has drawn attention recently as a
probable causal factor to elicit variable degrees of severity of
the disease in the human hosts. Moreover, MTB isolates
from patients with similar characteristics had remarkable
variation in transmission rates when studied in animal
models, again consistent with the idea of intrinsic biological
differences between strains [2]. The W/ Beijing, HN878 and
CDC1551 are some of the MTB strains that have been stud-
ied in detail to understand the effect of genetic and pheno-
typic variations of MTB on the virulence of the organism
and severity of the disease [3]. Initial mouse infection stud-
ies demonstrated that CDC1551 replicates more rapidly in
the lung than another reference strain known as Erdman
[3]. However, subsequently it was shown that CDC1551
replicate at a comparable level as H37Rv, Mycobacterium bovis
and other clinical isolates [4,5]. Experiments with human
monocytes revealed that different clinical isolates show
variability in rate of replication and survival in this model,
too [6].
Macrophages are the first line of defense in the lungs that
counter MTB. Ingestion of mycobacteria induces the release
of proinflammatory cytokines and chemokines, which even-
tually leads to the induction of an immune response. A key
player in the generation of Th1 response is interleukin-12
(IL-12), a cytokine produced mainly by the macrophages.
IL-12 has been shown to be crucial in the development and
sustenance of protective immunity against TB in mouse and
human studies [7–9].
Reactive nitrogen intermediates (RNI) are important effec-
tor molecules released by the macrophages in response to
mycobacterial infection. RNI are more important than reac-
tive oxygen intermediates (ROI) to control the mycobacterial
growth at least in case of Murine TB [10]. Tumor necrosis fac-
tor-alpha (TNF-a) controls intracellular mycobacteria in Mur-
ine macrophages through TNF-a inducible nitric oxide
synthase (iNOS)-dependent as well as TNF-a-iNOS-indepen-
dent pathways [11]. It was previously shown that MTB in-
duces a high production of nitric oxide (NO) along with the
production of TNF in patients with fresh active TB, but not
in MDR TB [12]. TNF-a is a pleiotropic cytokine produced pri-
marily by monocytes and macrophages and plays an impor-
tant role in the host immune response to tuberculosis [13].
In 1949, Haldane [14] proposed that the maintenance of
multiple genes that confer relative susceptibility of the hostto infectious diseases would be favored by evolution. Several
TB and candidate genes potentially involved in the immune
response to TB [15,16]. A strong hypothesis is in favor of a role
played by host factors in TB susceptibility because only 10% of
the infected individuals develop active clinical disease [17].
Therefore, an integrated approach is important and necessary
to understand the role played by the diversity of the host in
the context of the immune response and the variable patho-
genic potential of MTB strains.
In the present study, the differential effect of host and
pathogenic variability was investigated in an ex-vivo system
of host–parasite interaction. The pathogen variability repre-
sented by the virulent H37Rv, non-virulent H37Ra and a clin-
ical MDR strain of MTB, #591 (a TBd-1 positive and EAI clade
spoligotype). The host category included MDR-TB patients,
fresh active pulmonary TB patients and healthy volunteers.
The intracellular survival of all the above-mentioned
strains in MDM (monocyte derived macrophages) from differ-
ent categories of hosts and the immunologic response
parameters were assayed in terms of IL-12, TNF-a and NO
release. Interferon-gamma (IFN-c) receptor expression was
analyzed on the CD14 positive MDM as an indicator of
activation.Materials and methods
Subjects
Informed consents were obtained from patients and volun-
teers who took part in this study. Twenty-one HIV negative
patients, clinically and bacteriologically positive for MDR-TB
and 17 newly diagnosed patients suffering from fresh active
TB from Rajan Babu Institute of Pulmonary Medicine and
Tuberculosis (RBIPMT), Kingsway Camp, Delhi, India, were in-
cluded in the study. All the MDR-TB patients were infected
with tubercle bacilli resistant to at least INH and RIF. The
age of the patients ranged from 20 to 60 years, the average
age being 40.5 ± 12.27 years.
Ten healthy subjects of comparable age group without any
previous history of tuberculosis or any other disease were also
included in the study. All healthy volunteers had received the
BCG vaccination at birth. The study was approved by the eth-
ical committee of the Vallabhbhai Patel Chest Institute, where
this study was conducted.Isolation of PBMC and monocytes
Venous blood from TB patients and healthy volunteers was
drawn into heparinized vials, diluted 1:2 in Roswell Park
Memorial Institute (RPMI)-1640 medium, layered onto ficoll-
hypaque and centrifuged for 30 min at 2000 rpm. Peripheral
blood mononuclear cells (PBMC) were isolated from the inter-
face and washed in RPMI-1640. Approximately 2 · 106 PBMC
were placed in 6-well culture plates and incubated overnight
at 37 C. The next day non-adherent cells were removed by
washing in RPMI-1640.
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Adherent cells were 90% monocytes as determined by CD14
expression through flow cytometry (BD Biosciences) and ana-
lyzed through CELLQuest Software. The adherent monocytes
were incubated for 5 days in the RPMI-1640 medium supple-
mented with 10% autologous serum at 37 C in 5% carbon
dioxide (CO2). Morphological examination confirmed the mat-
uration of monocytes to macrophages.
Mycobacterial culture
The (#591) clinical isolate was recovered from the sputum of
a TB patient submitted to the laboratory (Dept. of Microbiol-
ogy, Vallabhbhai Patel Chest Institute) for investigation. The
drug sensitivity profile of the isolate was determined by
using the BACTEC-460 system. This clinical isolate was
found to be resistant to Isoniazid, Rifampicin, Streptomycin
and Ethambutol. MTB H37Rv, H37Ra and the #591 strain
were maintained in Lowenstein–Jensen (LJ) medium slants.
They were then grown in Middlebrook 7H9 broth (Difco, BD
Diagnostic Systems, Sparks, MN, USA) at 37 C for 2 weeks.
The mid-log phase cultures were pelleted, resuspended in
RPMI medium and passed through 8 l filter to form single-
cell suspension and aliquoted and stored at 70 C until
further use.
Strain typing
The (#591 MDR-TB) strain was genetically characterized by
IS6110 DNA fingerprinting, spoligotyping and mycobacterial
interspersed repetitive units (MIRU) typing [18].
Macrophage infection
The MDM isolated as mentioned earlier in Section 2.2 (Isola-
tion of PBMC and monocytes) were recharged with complete
RPMI medium supplemented with 10% autologous serum
without any antibiotic and were infected with single-cell sus-
pension cultures of #591 strain or H37Rv or H37Ra at multi-
plicity of infection (MOI) of 1:10 and incubated overnight.
The next morning they were washed repeatedly to remove
the extracellular bacteria and incubated further for another
48 h. The overnight infection of macrophages with MTB did
not affect the viability of the macrophages as was seen by
the MTT assay (data not shown). For assessment of phagocy-
tosis, the MDM were plated on sterile cover slips and in-
fected with single-cell suspension cultures of #591 strain or
H37Rv or H37Ra at MOI of 1:10 and incubated overnight.
The next morning cells were washed repeatedly to remove
the extracellular bacteria and incubated further for another
48 h. At 48 h of infection, the cover slips were washed with
PBS and the cells were fixed with 2% paraformaldehyde.
After washing, the cells were stained with auramine-rhoda-
mine dye to detect the phagocytized mycobacteria, and the
counter stain used for macrophages was PI (propidium io-
dide). The cover slips were mounted in buffered glycerol,
and intracellular mycobacteria were counted under a fluores-
cence microscope.CFU assay
The number of ingested and internalized mycobacteria with-
in the MDM was calculated by lysing the infected cells from
one of the wells in 1% Triton X 100. Serial dilutions of the ly-
sate were inoculated on LJ medium slants in duplicates. The
slants were incubated at 37 C for 3 weeks. At the end of
3 weeks, slants were taken out and colony forming units
(CFU) were calculated from the number of colonies of MTB
on the LJ slants, taking into consideration the dilution
factors.Nitric oxide release
The concentrations of NO in the culture supernatant of the
mycobacteria-infected macrophages were measured at 48 h.
The concentration of nitrite produced by MDM in response
to mycobacterial infection as a measure of the production
of NO was determined using Griess reagent at 540 nm by a
spectrophotometer. Briefly, 100 lL supernatant was removed
from culture wells, centrifuged at 400g for 10 min to make it
cell free and incubated with an equal volume of Griess re-
agent (1% sulfanilamide, 0.1% naphthyl ethylenediamine
dihydrochloride, 2.5% H3PO4) at room temperature for
10 min. The concentration of nitrite was determined by using
sodium nitrite as the standard.Cytokines assay
To determine the release of IL-12 and TNF-a, the supernatants
were harvested from the MDM culture of different study
groups infected with MTB phenotypes at 48 h of infection.
The supernatants were spun down at 10,000 rpm to remove
any cell debris. The cytokines TNF-a and IL-12 were assayed
in cell culture supernatants at 48 h by a solid phase sandwich
enzyme-linked immunosorbent assay (ELISA) using matched
antibody pairs according to the manufacturer’s instructions
(Prolab, Germany).IFN-c receptor expression
Expression of IFN-c receptor was observed on MDM at 48 h of
infection by using phycoerythrin (PE)-labeled antibody to IFN-
c receptor-1 (a chain, CD119) (BD Biosciences). MDM were
identified by using fluorescein isothiocyanate (FITC)-labeled
CD14 antibody (BD Biosciences). The cells were labeled and
fixed. The data was acquired by flow cytometry using fluores-
cence-activated cell sorter (FACS) Calibur and analyzed by
CELLQuest Software.Statistical analysis
The in vitro NO release, cytokine release and CFU were ana-
lyzed and the results were expressed as mean with stan-
dard error of mean (mean ± SEM). Student’s t-test and
Pearson coefficient of correlation were used to assess signif-
icance using Graph Pad Prism software (http://www.
graphpad.com).
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Survival of MTB phenotypes (MDR-TB) strain, H37Rv and
H37Ra) in MDM of different study groups
To examine the survival of phenotype variants of the MTB
intracellularly within the host cells, MDM from MDR-TB pa-
tients, fresh active TB patients and healthy individuals were
infected with #591, H37Rv and H37Ra separately at MOI of
1:10. After 48 h of infection, the intracellular mycobacteria
were released from the cells, serially diluted, plated on LJ
slants and CFU was counted after 21 days of incubation at
37 C.
The isolate #591 grew faster in the MDM of MDR-TB
patients, and the growth rate was least in MDM of healthy
volunteers (Fig. 1). This difference was statistically significant
(p < 0.005). H37Rv grew at the same rate as the #591 in MDM of
MDR-TB patients. In comparison, the growth of the attenu-
ated strain H37Ra was greatly restricted by the MDM of
MDR-TB patients (Fig. 1). This difference in the rate of survival
of #591 strain and H37Rv as compared with H37Ra was signif-
icant (p < 0.05) in the case of MDR-TB patients. However, when
the growth rate (CFU) of all three phenotypes were compared
between MDR-TB patients and the healthy individuals, the
CFU of H37Ra was found to be significantly higher in MDR-
TB MDM (p < 0.05) indicating thereby that MDR-TB patients’
ability to restrict even the attenuated mycobacterium were
compromised.
Notably, in the MDM of fresh active TB patients, the rate of
growth in terms of CFU was comparable for all three pheno-
types. However, the CFU of the #591 strain was much lower
than that in the MDM of MDR-TB patients (p = 0.05) (Fig. 1),
thus indicating that fresh active TB patients could control
the growth and survival of the #591 strain more efficiently
than the MDR-TB patients.
Although MDM of healthy volunteers could restrict the
growth of all three phenotypes of MTB, namely, #591, H37Rv
and H37Ra, the reduction of CFU was more in the case ofFig. 1 – The intracellular survival of the MTB strains in the MDM
subject categories: MDR-TB (n = 10), fresh active TB (n = 10) and
(MTB) strains, clinical drug resistant (#591), H37Rv and H37Ra at
as **mean ± SEM (standard error mean). Significant values are in
uuup < 0.0005; up < 0.05. Results show higher survival of #591 and
healthy subjects.H37Rv and H37Ra. In contrast, #591 strain could grow more
efficiently in MDM of volunteers, and this difference was sta-
tistically significant (p < 0.05).
The results from the three study groups point toward a
host-dependent differential ability to control the growth and
survival of different phenotypic variants of MTB (Fig. 1). This
observation may be an indication that the status of the im-
mune response of the host is one of the deciding factors for
the survival of mycobacteria in the host cells.Expression profile of IFN- receptor on the MDM of patients
and healthy volunteers in response to phenotypes of
M. tuberculosis
In order to understand whether the variation observed above
is a owing to a difference in the state of activation of the MDM
in different subject groups, MDM of MDR-TB patients, fresh
active TB patients and healthy individuals were infected with
#591, H37Rv and H37Ra in separate experiments. The percent-
age of CD14 positive MDM expressing the IFN-c receptor I
(CD119) at 48 h post infection were determined by flow
cytometry.
The level of IFN-c receptor-I expression on the CD14
positive MDM was significantly high in MDR-TB patients
(40.75 ± 5.57) as compared with healthy subjects (20.00 ±
6.84). In the case of fresh active TB patients, the percentage
of IFN-c receptor-I positive MDM was also higher (36.18 ±
5.984) as compared with healthy subjects (20.00 ± 6.84),
although the difference was not statistically significant.
When the MDM derived from MDR-TB patients, fresh active
TB patients or healthy individuals were infected with the
three phenotypic variants of MTB, the percentage of IFN-c
receptor positive MDM did not show any further significant
change. These results indicate that once internalized, the
intracellular growth and survival of the phenotypic variants
of MTB may not regulate the expression of IFN-c receptor on
the CD14 positive MDM (Fig. 2).. MDM (monocyte-derived macrophages) from different
healthy subjects (n = 8) were infected with M. tuberculosis
MOI of 1:10 in independent experiments. Results expressed
dicated as symbols. *p < 0.05; hp < 0.05; uup < 0.005;
H37Rv in MDM of MDR-TB patients as compared to MDM of
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in response to phenotypes of MTB
Nitric oxide (NO) released in response to drug-resistant and
drug-sensitive phenotypes of MTB (#591, H37Rv and H37Ra)
was estimated at 48 h post-infection. The spontaneous re-
lease of NO by MDM of healthy individuals was higher
(15.70 ± 2.19 lM/L), though not statistically significant, as
compared with the spontaneous release of NO by MDM from
MDR-TB and fresh active TB patients (Fig. 3).
In response to infection with #591, the NO released by
MDM of MDR-TB, fresh active TB patients and healthy individ-
uals was at basal level (Fig. 3). In response to the virulent
laboratory strain, the NO release was at the basal level. Inter-
estingly, however, in response to infection with attenuated
laboratory strain H37Ra, the release of NO from MDM from
both MDR-TB and fresh active TB patients was still at basal le-
vel, whereas healthy volunteers’ MDM produced significantly
higher NO (34.70 ± 7.76 lM/L, p < 0.05).IL-12 release by MDM of patients and healthy subjects in
response to phenotypes of MTB
MDM of MDR-TB, fresh active TB patients and healthy individ-
uals were either infected with #591, H37Rv and H37Ra or left
uninfected. At 48 h post-infection, supernatant from thewells
of infected/uninfected cells were collected and assayed for
the release of IL-12.
The basal level of IL-12 release was comparable in the
MDR-TB patients and healthy individuals (114.0 ± 37.38 and
164.8 ± 66.71 pg/ml, respectively). In contrast, basal level of
IL-12 in the MDM supernatant of fresh active TB patients
(26.88 ± 4.99 pg/ml) was significantly depressed as compared
with healthy subjects (p < 0.05) (Fig. 4).
MDM of MDR-TB patients, when infected with the #591
strain, released a higher concentration (221.5 ± 47.89 pg/ml)Fig. 2 – Expression of CD14 and IFNcR-I as markers of activation
included 21 MDR-TB patients, 17 fresh active TB patients and 1
*p < 0.05.of IL-12 as compared with the basal level (114.2 ± 37.38 pg/
ml). Following infection with H37Rv, the release of IL-12 was
also significantly up regulated (279.7 ± 53.54 pg/ml) (p < 0.05),
whereas in response to H37Ra, the release remained at the
basal level (133.1 ± 37.61 pg/ml).
MDM of fresh active TB patients, in response to infection
with #591 strain, released significantly higher concentration
of IL-12 (276.7 ± 64.48 pg/ml) as compared with depressed
spontaneous release (26.88 ± 4.99 pg/ml) (p < 0.0005). H37Rv
and H37Ra also induced significant up regulation of IL-12
secretion from MDM of fresh active TB patients
(156.0 ± 46.35 and 129.5 ± 34.32 pg/ml, respectively). However,
although relatively up regulated, since the initial concentra-
tion was very low, the absolute IL-12 levels were much lower
when compared to the concentration of IL-12 from the MDM
of the healthy individuals and MDR-TB patients.
In the case of healthy volunteers, the scenario presented
with a clear contrast; #591 drastically down regulated the
release of IL-12 (39.05 ± 8.95 pg/ml) from MDM of healthy vol-
unteers as comparedwith spontaneous release (164.8 ± 53.14).
Interestingly, however, in response to H37Rv and H37Ra, the
release of IL-12 was not much affected and remained compa-
rable with spontaneous release of IL-12 ( Fig. 4). Thus, in
healthy subjects, the #591 showed a definite down regulation
of the IL-12 release, whereas in the TB patients (MDR-TB and
fresh active TB), the same strain demonstrated an up regula-
tory response.
TNF-a released by MDM of patients and healthy subjects in
response to phenotypes of M. tuberculosis
MDM of MDR-TB, fresh active TB patients and healthy individ-
uals were either infected with #591, H37Rv and H37Ra or left
uninfected to assay for spontaneous release of TNF-a. At
48 h post-infection, supernatant from the wells of infected/
uninfected cells were collected and assayed for the release
of TNF-a.on the MDM (monocyte-derived macrophages). The study
0 healthy subjects. Results are expressed as percentage.
Fig. 4 – Trends of IL-12 release by MDM of patients and healthy individuals. MDM (monocyte-derived macrophages) of MDR-
TB patients (n = 21), fresh active TB patients (n = 17) and healthy subjects (n = 10) were assayed for the release of IL-12, in
response to infection with #591, H37Rv and H37Ra. Significant values are indicated with symbols. **p < 0.05; hhhp < 0.0005;
hhp < 0.005; hhp < 0.005; up < 0.05. (a) Shows the variable IL-12 release by MDM of MDR-TB patients in response to MTB
phenotypes. (b and c) Represents the trend of IL-12 released by MDM of fresh active TB patients and healthy volunteers
respectively, in response to MTB phenotypes. It may be noted that in response to infection with #591, IL-12 release shows
sharp down regulation in the MDM of healthy individuals, whereas, in contrast, #591 infection significantly up regulates IL-
12 release by MDM of fresh active TB patients. However, H37Rv, a virulent laboratory maintained strain, elicited high IL-12
release in all three groups.
Fig. 3 – Nitric oxide estimation. MDM (monocyte-derived macrophages) culture from different subject categories; MDR-TB
patients (n = 21), fresh active TB patients (n = 17) and healthy subjects (n = 10). The results are expressed as mean ± SEM.
*p < 0.05; hp < 0.05.
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of MDR-TB patients and fresh active TB patients was de-
pressed significantly (53.44 ± 16.84 and 27.56 ± 11.85 pg/ml,
respectively) as compared with the same from healthy volun-
teers (150.8 ± 48.83 pg/ml).
The #591 induced an enhanced release of TNF-a from
MDM of MDR-TB patients (113.6 ± 30.74 pg/ml) as compared
with the spontaneous release (53.44 ± 16.84 pg/ml). The viru-
lent strain H37Rv also induced a significantly higher release
of TNF-a as compared with spontaneous release (p < 0.005).
The avirulent strain H37Ra induced a high but not-significant
release of TNF-a (Fig. 5).
The MDM of fresh active TB patients in response to #591
released a significantly higher concentration of TNF-a
(223.8 ± 59.49 pg/ml) as compared with the spontaneous re-
lease (27.56 ± 11.85). In response to H37Rv, the release was sig-
nificant, and in response to H37Ra, the release was high but
not significant (Fig. 5).
On the other hand, in the case of healthy volunteers, the
#591 down regulated the TNF-a release from theMDM so dras-
tically that the concentration (38.20 ± 21.27 pg/ml) reached
below the level of spontaneous release (150.8 ± 48.83 pg/ml).
In response to H37Rv and H37Ra, however, the TNF-a releaseFig. 5 – Trends of TNF-a release by MDM of patients and healthy i
patients (n = 17) and healthy subjects (n = 10) were assayed for th
H37Rv and H37Ra. Significant values are indicated with symbols
trend of TNF-a released by MDM of MDR-TB patients in respons
response to infection with #591, TNF-a release shows drastic dow
contrast, #591 infection significantly up regulates TNF-a release
virulent laboratory maintained strain, elicited high TNF-a relearemained comparable with the concentration of spontaneous
release (Fig. 5).
Discussion
Variability in the severity and extent of the disease course in
TB has fueled speculation regarding the respective contribu-
tion of host resistance and bacterial virulence [19]. Also, it
has remained an intriguing question to understand the pre-
cise role played by the immune status of the host in such
an interaction. There is no clear explanation to date as to
why only a fraction of the population exposed to MTB devel-
ops clinical disease.
Comprehensive knowledge of the genetic and molecular
bases of virulence is central to understanding the pathogene-
sis of diseases owing to intracellular pathogens. The virulent
MTB strain H37Rv and its avirulent counterpart H37Ra have
been studied extensively in animal models, and the genetic
and phenotypic differences between these two strains are un-
der intensive investigation [20]. In addition to the standard
reference strains, studies have also been conducted using
phenotypic variants of clinical isolates of MTB, such asW/Bei-
jing strain, CDC1551, etc. [5]. All of these studies focused onndividuals. MDM of MDR-TB patients (n = 21), fresh active TB
e release of TNF-a in response to infection with #591 strain,
. **p < 0.005; hp < 0.05; hhp < 0.005; up < 0.05. (a) Represents the
e to MTB phenotypes. (b and c) It may be noted that in
n regulation in the MDM of healthy individuals, whereas, in
by MDM of fresh active TB patients. However, H37Rv, a
se in all three study groups.
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context of virulence and their effect on the immune parame-
ters either in animal models or ex-vivo cultured humanmono-
cytes and MDM. Virulence of MTB strains has traditionally
been assessed in terms of the ability of bacilli to replicate
within specific organs of mice and guinea pigs following aer-
osol infection. Such studies are time-consuming and expen-
sive. Furthermore, although mouse and guinea pig models
can effectively assess the virulence of MTB strains, animal
studies may be less helpful in understanding virulence in
the context of human TB and clarifying the mechanism by
which the bacilli interact with or subvert host immune re-
sponse [5].
Li et al. [6] described a method for low level of infection of
human blood monocytes in which patterns of intracellular
growth of virulent MTB (H37Rv), attenuated vaccine strain
M. bovis BCG, and avirulent MTB (H37Ra) correlated with the
observation in the animal model [21].
In the present study, this ex vivo low-level infection model
was applied to infect MDM derived from healthy volunteers
and TB patients. The virulence of a clinical MDR-TB strain
#591 isolated from a patient suffering from pulmonary TB
was assessed in the host parasite interaction using this mod-
el. This strain is a multidrug-resistant ‘‘old world’’ strain [22]
that showed a three-banded pattern (low banding pattern)
by IS6110 RFLP and which belonged to the East African-Indian
(EAI) clade by spoligotyping (data not shown), which is a com-
mon spoligotype found in the Delhi region [18]. The standard
virulent laboratory strain H37Rv and the attenuated strain
H37Ra were included as phenotype variants of MTB. The
healthy individuals and pulmonary TB patients, both fresh
active TB and MDR-TB, were the host subjects included in
the study. The question asked was whether the intracellular
survival of MTB in human MDM, an attribute of pathogenic
potential of the MTB strains, can be modulated by the vari-
ability in the immune status of the hosts or the phenotype
of the pathogen?
It was found that the intracellular growth rate of the #591,
in terms of CFU, differed greatly in the MDM of the three
study groups. Strain #591 grew faster in the MDM of MDR-
TB patients, as shown by a very high CFU (4.14 · 103), com-
pared with fresh active TB patients (2.7 · 103) and healthy
individuals (2.05 · 103) (Fig. 1). Zhang et al. [20] in a study with
human macrophages observed that all the four patients
isolates used in their study proliferated more rapidly inside
the macrophages than H37Rv. Their study, however, did not
include any patient groups and used macrophages from
healthy subjects only. Moreover, in that study no immune
parameters were investigated.
It was surprising to note that while the growth rate of #591
was comparable in fresh active TB patients and healthy vol-
unteers, the immune response parameters showed a strik-
ingly reverse trend. TNF-a and IL-12 were assessed as the
parameters of immune response because both in vivo and
in vitro studies have suggested a role for TNF-a in contain-
ment of intracellular MTB [23]. In the present study, it was ob-
served that following the challenge with #591 the TNF-a level
took a significant sudden dip (p < 0.05) in the case of healthy
volunteers. Such a significant down regulation of TNF-a sug-
gests that MDM from immune-competent healthy subjectsis able to contain the growth of the clinical strain #591 and
regulate the pro-inflammatory cytokine TNF-a, supporting
the hypothesis that the ability of MTB to stimulate production
of TNF-a may serve primarily to promote pathogenesis rather
than protection [28]. In contrast, the same strain, #591, shot
TNF-a release from the MDM of fresh active TB patients many
fold higher from the basal value (p < 0.005) (Fig. 5). These pa-
tients were suffering from active infection, and the MDM
were already in a state of activation, as evidenced by the
IFN-c RI level (Fig. 2). The challenge with the clinical strain
#591 led to a significant up regulation of TNF-a release. In
the case of MDR-TB, the TNF-a level was up regulated,
although this increase was not statistically significant, possi-
bly because the basal level of TNF-a in MDR-TB patients was
already high.
Interestingly, the CFU for the other two strains of MTB,
namely H37Rv and H37Ra, in the MDM of fresh active TB pa-
tients were similar and comparable with that of #591 (2.5 · 103
and 2.04 · 103, respectively), although the TNF-a release
showed a variable response. The TNF-a release was least in
response to H37Ra and higher in response to H37Rv (Fig. 5).
This differential expression of TNF-a correlating with the in-
crease in the virulence of the challenge strains has been
noted by others also [21]. Rook et al. [24] observed a greater
induction of TNF-a by human monocytes in response to
H37Rv than to BCG. Cho et al. [25] reported higher levels of
TNF-a mRNA in guinea pig macrophages infected with
H37Rv compared with H37Ra. In the past, there was some
controversy surrounding the question as to whether attenu-
ated or virulent mycobacteria induce higher levels of TNF-a
[26]. In that context, the results of this study indicate that
the host’s immune status plays a very important regulatory
role in the release of TNF-a, because attenuated MTB strain
H37Ra up regulates TNF-a release in healthy subjects in com-
parison with minimal up regulation in fresh active TB and
MDR-TB patients (Fig. 5). Thus, the emerging picture suggests
that the up or down regulation of TNF-a in response to myco-
bacteria will depend on the immune status of the individuals
as well as the infecting MTB strain phenotype. While standard
laboratory strains may give comparable results, the wild type
of clinical strains circulating in the population possibly may
elicit a more variable response.
The results of the present study using #591, a drug-
resistant clinical old world strain, representing a common
spoligotype circulating in the local population, is of sharp
down regulation of TNF-a in healthy subjects and up regula-
tion in TB patients. The IL-12 release, as an indicator of
MDM activation, was also included in the present study. IL-
12 enhances IFN-c production and cytotoxicity of NK and T
cells, including ab (CD4+ and CD8+) and cd T-cell receptor bear-
ing cells [27,28]. IL-12 also favors the development of Th-1 like
T-cell responses by antagonizing IL-4 and IL-10 and down reg-
ulating Th-2 responses [29,30]. In Murine models, administra-
tion of exogenous IL-12 enhances immunity against MTB. Not
much is known, however, about the ability of mycobacteria to
induce IL-12 production by humanmacrophages, the principal
host target for themycobacteria. The results of the IL-12 assay
in this study showed a trend that is similar to the profile
observed for TNF-a release; #591 drastically down regulated
the IL-12 level in healthy subjects whereas in fresh active TB
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tients, the IL-12 level was also raised above the basal value
in response to infection with #591 that ran in parallel to the
profile of TNF-a release. The present observation that IL-12 re-
lease is modulated by the different phenotypes of MTB infect-
ing MDM from different types of hosts draws support at least
from two recent studies [31,32]. The study by Fulton et al. [31]
demonstrated that the IL-12 production by humanmonocytes
is dependent on phagocytosis of MTB by the monocytes. The
second study, by Li et al. [32], used MDM from healthy volun-
teers to study the uptake of MTB under different environmen-
tal conditions. They observed significantly lower IL-12 and
TNF-a release by MDM infected by MTB grown under different
environmental conditions in comparison with H37Rv cultured
under standard laboratory conditions. The results of this
study reporting highly significant down regulation of TNF-a
and IL-12 by the clinical strain #591 in healthy subjects corrob-
orates with their findings.
The overall emerging scenario reveals that in response to
the challenge by the three different strains of MTB, the cyto-
kine profile of the MDM of healthy volunteers was the reverse
of that in fresh active TB patients; the picture somewhat
blurred in MDR-TB patients. Here, all three phenotypes of
MTB lead to up regulation of IL-12 and TNF-a. But this rise
had no effect on the control of intracellular growth of MTB.
In spite of high IL-12 and TNF-a, the #591 and H37Rv (and also
H37Ra) grew very efficiently inside the MDM of the MDR-TB
patients. This could mean that the MDM from these patients
are on a state of sustained activation, but the intracellular
machinery to control mycobacterial growth is impaired. High
IFN-cRI expression but generally unaltered NO levels (Fig. 2)
as observed in the MDR-TB patients may be an indicator of
this possibility. The findings of this study clearly indicate that
the release of TNF-amay not be a global indicator of virulence
of a strain. TNF-a release may be differentially regulated in re-
sponse to the same strain, depending upon the immune sta-
tus of the responding host. Thus, this picture further supports
the hypothesis that in addition to the phenotype variation of
the mycobacteria, the immune status of an individual will
greatly influence the outcome of the host-pathogen interac-
tion. These results may have a bearing on the future endeav-
ors in vaccine development and TB control strategies.
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